ImmunityBio's Commercial Ramp Now Carries the Weight of Its Entire Investment Thesis

ImmunityBio Inc (IBRX) is scheduled to report first-quarter 2026 earnings on May 11, 2026, with analysts expecting a loss of $0.08 per share. The biotech company faces a critical test as investors assess whether its recent commercial momentum can continue following a disappointing Q1 miss that broke a two-quarter streak of earnings beats. With the stock trading 92% above its 200-day moving average and analyst price targets implying 74% upside, this report will determine whether IBRX's transformation story remains intact or if execution challenges are emerging.

Part 1: Earnings Preview

ImmunityBio is a clinical-stage immunotherapy company focused on developing therapies for cancer and infectious diseases, with its lead product ANKTIVA recently gaining FDA approval for bladder cancer treatment. The company's commercial launch and pipeline progress have made it a closely watched name in the oncology space.

For the quarter ending March 2026, analysts expect IBRX to report a loss of $0.08 per share on estimated revenue of approximately $43.17 million. The company most recently reported Q1 2026 results with an actual loss of $0.09 per share, missing estimates by 12.50% and breaking a positive trend. Compared to the same quarter last year when IBRX posted a loss of $0.10 per share, the current estimate represents 20% year-over-year improvement in losses.

Three key themes define this earnings story:

ANKTIVA Commercial Trajectory: Following FDA approval and the dramatic 700% revenue surge to $113 million in 2025, investors are laser-focused on whether ANKTIVA's commercial adoption can sustain its momentum. The Q4 2025 beat demonstrated strong uptake, but the Q1 2026 miss raised questions about demand consistency. Sequential quarterly growth rates and physician adoption metrics will be critical indicators of the drug's long-term commercial viability.

Path to Profitability: With losses narrowing from $0.38 per share in 2025 to an estimated $0.31 in 2026, the company's trajectory toward breakeven is under scrutiny. Management's ability to scale revenue while controlling operating expenses will determine whether IBRX can achieve profitability by 2027, as some analysts project with estimates ranging from a $0.07 to $0.28 loss per share.

International Expansion Execution: Management has emphasized plans to expand ANKTIVA internationally, which could significantly broaden the addressable market. Investors will watch for concrete updates on regulatory filings, partnership discussions, and commercialization timelines in key markets outside the United States.

Analyst commentary ahead of the release reflects cautious optimism. The five Strong Buy ratings and single Hold rating demonstrate confidence in the company's long-term potential, with price targets ranging from $11.00 to $23.00. However, the recent earnings miss and the company's history of volatile post-earnings price action—including a 13% drop on the day of the March 2025 report—suggest investors should brace for potential volatility regardless of whether IBRX beats or misses expectations.

Part 2: Historical Earnings Performance

ImmunityBio has demonstrated an improving but inconsistent earnings track record over the past four quarters. The company beat estimates in two consecutive quarters (Q3 2025 with a 30% beat and Q4 2025 with a 25% beat) before missing in Q1 2026 by 12.50%. The Q2 2025 report came in exactly at estimates.

The pattern reveals a company in transition, with losses generally trending smaller over time but execution remaining uneven. The two strong beats in the second half of 2025 coincided with ANKTIVA's commercial launch momentum, while the recent Q1 2026 miss suggests the path to consistent profitability may be bumpier than investors hoped. The magnitude of beats when they occur (25-30%) has been substantial, but the inability to maintain that momentum into Q1 2026 raises questions about quarterly predictability.

This inconsistency makes the upcoming Q1 2026 report particularly important—another miss could signal deeper execution challenges, while a return to beating estimates would reinforce the narrative that Q1 was merely a temporary setback in an otherwise positive trajectory.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

ImmunityBio typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior around IBRX earnings reveals extreme volatility, with an average absolute Day 0 move of 7.74% and Day +1 move of 6.57%. The most dramatic reaction came with the February 2026 report, when the stock surged 12.99% on Day 0 and extended gains to 17.50% by Day +1 following the strong Q4 2025 beat. Conversely, the March 2025 report triggered a 13.37% Day 0 decline despite beating estimates, illustrating how sensitive the stock is to guidance and qualitative factors beyond the headline numbers.

The data shows IBRX tends to experience larger intraday ranges than directional moves, with Day 0 ranges averaging 10.26% and Day +1 ranges averaging 12.35%. This suggests significant intraday volatility and potential whipsaw action as traders digest results. Recent reports have generally trended toward larger moves, with the last three earnings events producing Day +1 moves ranging from 3.37% to 17.50%, indicating heightened investor sensitivity to the company's commercial execution story.

Part 2.2: Options Market Expected Move

The options market is pricing an 10.69% expected move through May 15, 2026, which sits above the historical Day 0 average of 7.74% but below the Day +1 average of 12.35%. This suggests options traders are anticipating volatility consistent with IBRX's recent history, though not at the extreme levels seen in the February 2026 report when the stock moved 17.50% by Day +1.

Part 3: What Analysts Are Saying

Analyst sentiment on ImmunityBio remains decidedly bullish despite the recent Q1 2026 earnings miss. The consensus rating stands at 4.67 out of 5.0, with 5 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 6 analysts covering the stock. The average price target of $14.80 implies 74% upside from the current price of $8.51, with individual targets ranging from a low of $11.00 (29% upside) to a high of $23.00 (170% upside).

The sentiment trend is classified as unchanged over the past month, indicating analysts have maintained their conviction despite the Q1 miss. The rating of 4.67 reflects near-unanimous bullishness, with only a single Hold rating preventing a perfect Strong Buy consensus. This stability suggests the analyst community views the recent earnings disappointment as a temporary setback rather than a fundamental shift in the investment thesis.

The wide range in price targets—from $11.00 to $23.00—reveals differing views on execution risk and the ultimate commercial potential of ANKTIVA. The most optimistic analysts appear to be modeling aggressive market penetration and successful international expansion, while more conservative estimates likely factor in commercialization challenges and the competitive landscape in bladder cancer treatment. Regardless of the range, even the low-end target implies meaningful upside, underscoring the Street's belief that IBRX remains undervalued relative to its opportunity.

Part 4: Technical Picture

ImmunityBio enters earnings with strong technical momentum, as the Barchart Technical Opinion has surged to an 88% Buy signal, up dramatically from 40% Buy just one week ago and 40% Buy one month ago. This sharp strengthening reflects accelerating bullish momentum heading into the May 11 report.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming, suggesting some consolidation or hesitation in the immediate timeframe
• Medium-term (100% Buy): Strong buy signal across all medium-term indicators points to robust momentum in the intermediate trend
• Long-term (100% Buy): Unanimous buy signal reflects powerful long-term uptrend momentum that has carried the stock significantly higher over extended periods

Strong and Strengthening trend characteristics suggest IBRX is in an accelerating uptrend with building momentum across multiple timeframes, creating a supportive technical backdrop for the earnings release.

The stock is trading above all major moving averages, including the 5-day ($7.93), 10-day ($7.51), 20-day ($7.64), 50-day ($7.94), 100-day ($6.46), and 200-day ($4.43). The current price of $8.51 represents a 92% premium to the 200-day moving average, indicating an extended rally that has carried shares substantially higher over the past year. While the technical setup is undeniably bullish with the stock above all key support levels, the magnitude of the advance and the 10.69% expected move suggest investors should prepare for significant volatility. A beat could propel shares toward the $9.42 upper range implied by options, while a miss risks a pullback toward the $7.60 lower bound—though the strong technical foundation may limit downside if the long-term growth story remains intact.